Hikma Pharmaceuticals delivered significant progress across environmental sustainability, healthcare access, employee development, ethical governance, and community engagement during 2025. The company strengthened its sustainability framework through a Double Materiality Assessment aligned with European Sustainability Reporting Standards (ESRS), focusing on four pillars: Advancing Health and Wellbeing, Empowering People, Protecting the Environment, and Operating Transparently and Ethically.
Environmental sustainability remained a key priority as Hikma continued reducing its carbon footprint across global operations. The company reported a 16 percent reduction in Scope 1 and Scope 2 greenhouse gas emissions compared with its 2020 baseline, lowering total emissions from 155,142 tonnes of CO₂ equivalent (tCO₂e) in 2020 to 130,743 tCO₂e in 2025. This represents a reduction of more than 24,000 tCO₂e, or nearly 24,400 tCO₂e, over the five-year period. Hikma has committed to reducing Scope 1 and Scope 2 emissions by 25 percent by 2030 and continues to integrate climate action into its long-term business strategy.
The company has not yet announced a formal net-zero target, but climate change, greenhouse gas emissions, water stewardship, and environmental management remain material sustainability priorities. Hikma continues to improve energy efficiency, assess climate-related risks and opportunities, and strengthen environmental governance across its operations, Hikma Pharmaceuticals Sustainability Report 2025 indicated.
Renewable energy investments contributed to Hikma’s decarbonization progress. Since 2021, the company has increased operational renewable energy capacity by 354 percent. Annual electricity generation from onsite solar installations reached 5,000 MWh, while a new 1 MW solar park in Jordan expanded clean energy generation capacity and reduced reliance on conventional power sources. Renewable energy adoption, energy efficiency improvements, and operational modernization across Hikma’s 29 manufacturing facilities are expected to play a major role in achieving future emissions targets.
Access to affordable, high-quality medicines remains central to Hikma’s sustainability strategy. The company announced a $1 billion investment program in the United States through 2030 to expand manufacturing and research and development capabilities for essential generic medicines. This initiative builds on more than $4 billion invested in the US over the past 15 years to strengthen medicine availability and supply-chain resilience.
Healthcare access expanded significantly during 2025, with Hikma delivering medicines and treatments to 222 million patients worldwide. To support innovation and future growth, the company invested more than $150 million in research and development, representing 4.5 percent of core revenue. These investments supported the launch of 84 new products designed to improve treatment availability and address evolving healthcare needs across global markets.
Hikma also strengthened efforts to reduce emissions throughout its value chain. The company engaged suppliers responsible for more than 55 percent of its total Scope 3 carbon footprint. Collaboration initiatives focused on reducing emissions linked to pharmaceutical packaging, cold-chain logistics, refrigeration systems, and inhaler propellants, helping advance broader supply-chain decarbonization goals.
Employee wellbeing and workforce development remained important priorities. Hikma achieved an employee engagement score of 73 percent and an employee enablement score of 69 percent. Employees received an average of 7.9 hours of learning and development training during the year. The company also continued to focus on employee wellbeing, inclusivity, professional development, health, safety, and human rights protections across its global workforce.
Community investment generated substantial social impact during the year. Hikma donated medicines valued at $2.6 million globally and made $3.3 million in charitable donations. Community programs reached 566,780 beneficiaries through 132 engagement activities. Employees contributed 8,060 volunteering hours through the participation of 3,480 volunteers, supporting healthcare access, community development initiatives, and emergency response programs.
Ethical governance remained a cornerstone of Hikma’s sustainability framework. Mandatory Code of Conduct, ethics, and compliance training achieved a 99 percent completion rate among employees. Supplier assessments showed that 92 percent of surveyed suppliers demonstrated strong alignment with Hikma’s Supplier Code of Conduct, supporting responsible sourcing, labor rights, environmental management, and ethical business practices throughout the value chain.
The company’s environmental performance also received external recognition. Hikma achieved a B score for Climate Change and a B score for Water Security in the 2025 Carbon Disclosure Project assessment, reflecting progress in environmental stewardship and sustainability management.
Tim Brooks, Vice President Sustainability at Hikma Pharmaceuticals, said the company remains focused on creating long-term value through healthcare access, environmental responsibility, employee development, and ethical business conduct. He noted that while access to medicine remains at the heart of Hikma’s sustainability strategy, the company’s four sustainability pillars support long-term success for patients, employees, communities, and other stakeholders.
Hikma Pharmaceuticals’ 2025 sustainability performance highlights measurable achievements across climate action and renewable energy. Key figures include a 16 percent reduction in Scope 1 and Scope 2 emissions, emissions declining from 155,142 tCO₂e to 130,743 tCO₂e, a target of 25 percent emissions reduction by 2030, a 354 percent increase in renewable energy capacity since 2021, 5,000 MWh of annual solar electricity generation, and a new 1 MW solar park.
SHAFANA FAZAL
